Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Cancer Immunol Res. 2017 Jul 3;5(8):685–694. doi: 10.1158/2326-6066.CIR-16-0330

Figure 6. Comparison of the effect of SS1P with an immunotoxin targeting human CD25.

Figure 6

(A) Western blot comparing mesothelin expression in 66C14-M tumor with 66C14-M cultured cells. (B) Three day WST-8 cytotoxicity assay with 66C14-M cells showed that a high concentration of 5 μg LMB-2 is required for cytotoxic effect. C–E. Individual growth curves of 66C14-M tumors treated with either anti-CTLA-4 and intratumoral PBS (C), anti-CTLA-4 and 5 μg dose SS1P (D), or anti-CTLA-4 and 5 μg dose LMB-2 (E). Pooled data from two experiments is presented. The number of mice in complete remission and total mice per group is shown in parentheses. Thick arrows mark the days of intatumoral injections, Thin arrows mark the days of i.p. injections. (F) Survival of mice treated with anti-CTLA-4 and either SS1P or LMB-2 was significantly longer than that achieved with PBS and anti CTLA-4 (P < 0.0001).